Our Pricing

Understanding the Mounjaro Dosage Chart: A Complete UK Guide

Published on: June 03, 2026

If you're researching the mounjaro dosage chart UK schedule, understanding the structured dose escalation is essential for safe, effective treatment. Mounjaro (tirzepatide) follows a gradual progression from 2.5mg to a maximum of 15mg over several months, allowing your body to adapt whilst minimising side effects. At Cured Pharmacy, our UK prescribers assess your individual needs and guide you through each dosage stage with transparent pricing from £135.00.

The Standard Mounjaro Dosage Chart Explained

Mounjaro follows a structured dose escalation protocol licensed by the MHRA. All patients begin with a 2.5mg once-weekly injection for the first four weeks, regardless of weight or medical history. This starting dose is not intended for weight loss but serves as an initiation period, allowing your body to adjust to tirzepatide's effects on GIP and GLP-1 receptors [1].

After four weeks, your dose increases to 5mg weekly — the first maintenance dose where weight loss typically becomes noticeable. If tolerated well and further weight loss is needed, your prescriber may increase the dose every four weeks through 7.5mg, 10mg, 12.5mg, and finally 15mg. Each escalation step is determined by your clinical response, tolerability, and weight loss progress [1].

Clinical trials demonstrate that higher doses produce greater weight reduction, but not all patients require the maximum 15mg dose. In the SURMOUNT-1 trial, participants on 10mg tirzepatide achieved an average 19.5% body weight reduction over 72 weeks, whilst those on 15mg averaged 20.9% — a modest difference that must be weighed against potential side effects [2].

Why Gradual Dose Escalation Matters

The four-week intervals between dose increases are not arbitrary. Tirzepatide's dual receptor activation affects gastrointestinal motility, and abrupt dose increases significantly raise the risk of nausea, vomiting, and diarrhoea. Gradual escalation allows your digestive system to adapt, reducing the likelihood of treatment discontinuation due to side effects [1][3].

Mounjaro Dosage Chart vs Wegovy: Key Differences

Whilst both medications follow weekly injection schedules, their dosing structures differ considerably. Wegovy (semaglutide) escalates from 0.25mg to a maximum of 2.4mg over 16-20 weeks, with five dose levels. Mounjaro offers six dose levels and a longer escalation period, reflecting tirzepatide's dual-agonist mechanism and higher potency [2][4].

The maximum doses are not directly comparable due to different molecular structures. However, clinical head-to-head data suggests that Mounjaro 15mg produces greater average weight loss than Wegovy 2.4mg. In comparative analyses, tirzepatide demonstrated superior efficacy across all dose levels when matched against semaglutide [2][4].

Your prescriber's choice between these medications depends on multiple factors beyond efficacy alone — including your medical history, previous GLP-1 experience, injection preference, and cost considerations. Both require prescription-only access through a UK-registered prescriber following clinical assessment.

Common Side Effects at Each Mounjaro Dose Level

Gastrointestinal side effects are most common during the first eight weeks and following each dose increase. At the 2.5mg starting dose, approximately 20-25% of patients experience mild nausea, typically resolving within one to two weeks. This percentage increases slightly with each escalation, peaking at around 30-35% when moving to 10mg or higher doses [1][3].

Diarrhoea and constipation follow similar patterns, affecting 15-20% of patients at lower doses and up to 25% at maximum doses. These effects are generally transient and manageable with dietary adjustments — eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce gastrointestinal discomfort [3].

More serious side effects are rare but require immediate medical attention. These include severe abdominal pain (potential pancreatitis), persistent vomiting leading to dehydration, visual changes, or signs of thyroid issues. Your prescriber will review your full medical history before prescribing Mounjaro, as it is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Managing Side Effects During Dose Escalation

If side effects become problematic at any dose level, your prescriber may recommend staying at your current dose for an additional four weeks before escalating further. Some patients achieve their weight loss goals at 7.5mg or 10mg and never require higher doses. The optimal maintenance dose is the lowest dose that produces clinically meaningful weight loss with tolerable side effects.

How Long Should You Stay on Each Mounjaro Dose?

The standard protocol recommends four weeks at each dose level before escalation. However, clinical practice allows flexibility based on individual response. If you experience significant side effects or rapid weight loss at a particular dose, your prescriber may extend that dose period to eight weeks or longer [1].

Weight loss velocity typically decreases over time as your body approaches a new metabolic set point. During the first three months on maintenance doses (5mg and above), expect steady weekly weight reduction. After six months, weight loss usually plateaus, and the medication's primary role shifts to weight maintenance rather than continued reduction [2].

Long-term treatment duration varies by individual. Clinical trials followed patients for up to 72 weeks, but real-world use often extends beyond this timeframe. NICE guidance suggests ongoing treatment is appropriate as long as clinically meaningful weight loss is maintained and side effects remain tolerable. Your prescriber will conduct regular reviews every three to six months to assess ongoing suitability [5].

Mounjaro Dosage Chart for Different Patient Groups

The standard dosage chart applies to most adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. However, certain patient groups require modified approaches. Older adults (over 65) typically follow the same escalation schedule but may require more cautious monitoring due to increased risk of dehydration from gastrointestinal side effects [1].

Patients with renal impairment can use Mounjaro without dose adjustment in mild to moderate cases, but those with severe renal impairment or end-stage renal disease have limited clinical data. Your prescriber will assess kidney function before initiating treatment and monitor it periodically [1].

Mounjaro is not licensed for use in patients under 18, during pregnancy, or whilst breastfeeding. Women of childbearing potential should use effective contraception during treatment and discontinue Mounjaro at least two months before planned conception. If you have type 2 diabetes and take other glucose-lowering medications, your prescriber may need to adjust those doses — particularly insulin or sulfonylureas — to prevent hypoglycaemia [1][3].

Dose Adjustments for Concurrent Medications

Tirzepatide delays gastric emptying, which can affect the absorption of oral medications. If you take medications with narrow therapeutic windows (such as levothyroxine or oral contraceptives), your prescriber may recommend taking them at least one hour before or four hours after your Mounjaro injection to ensure consistent absorption [1].

Accessing Mounjaro Through Cured Pharmacy

Mounjaro is available at Cured Pharmacy with transparent upfront pricing and requires completion of a free online consultation with a UK-registered prescriber. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every consultation to ensure Mounjaro is clinically appropriate for your individual circumstances.

Your consultation covers medical history, current medications, weight loss goals, and previous weight management attempts. If approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and delivered in discreet packaging, typically within 1-3 working days. All Mounjaro pens supplied are genuine UK-licensed medicines sourced through regulated channels.

Follow-up consultations are included at no additional cost, allowing your prescriber to monitor progress, adjust doses, and address any concerns throughout your treatment journey. You'll receive clear injection technique guidance and dosage schedule information with your first supply, ensuring you understand exactly when and how to escalate your dose safely.

What to Expect During Your Consultation

The online consultation takes under three minutes to complete and asks clinically relevant questions about your weight history, existing health conditions, and lifestyle factors. Honesty is essential — withholding information about medical conditions or medications can lead to unsafe prescribing decisions. All information is handled confidentially in accordance with UK data protection regulations and reviewed only by registered healthcare professionals.

Scientific References

1. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [TA1003]. https://www.nice.org.uk/guidance/ta1003 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and may not be suitable for everyone. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to treatment.